search
Back to results

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

Primary Purpose

High Blood Pressure

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Nebivolol
Metoprolol XL
Sponsored by
Emory University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for High Blood Pressure focused on measuring Nitric Oxide, Adrenergic beta-Antagonists, Antihypertensive Agents, Vasodilator Agents, Anti-Arrhythmia Agents, Sympatholytics, Vascular Resistance, Neurotransmitter Agents, Cardiovascular Diseases, Metoprolol succinate, Therapeutic Uses, Metoprolol, Vascular Diseases, Nebivolol, Cardiovascular Agents, Endothelium-Dependent Relaxing Factors

Eligibility Criteria

21 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or post-menopausal females aged 18-80 years.
  • Subjects self-identified as black or African-American.
  • Diagnosis of hypertension.
  • Patients on current anti-hypertensive therapy that does not include beta blockade should have BP >135/85.
  • Patients on anti-hypertensive therapy including beta blockers will have their beta blockers discontinued gradually over 2 weeks before enrolment.
  • Concomitant therapy: Patients will be allowed to be on concomitant therapy with aspirin, statins, thiazide diuretics, calcium antagonists (for treatment of hypertension), clonidine, or vasodilators. Patients will be on stable medical therapy for at least 2 months before recruitment. Patients with previous treatment with beta adrenergic blockers (metoprolol, propranolol, atenolol, and labetalol) will also be eligible to participate, but will be randomized to the study beta blocker.

Exclusion Criteria:

  • Initiation or change in dose of statin or other anti-hypertensive therapy within 2 months before the study
  • Inability to return to Emory for follow-up testing
  • Age < 21 or >80 years
  • Premenopausal females with potential for pregnancy
  • Acute infection in previous 2 weeks
  • On angiotensin antagonists (ACE inhibitors or ARBs)
  • History of substance abuse
  • Current neoplasm
  • Chronic renal failure [creatinine > 2.5 mg/dL] or liver failure (liver enzymes >2X normal)
  • Acute coronary syndrome, Class IV heart failure, CVA, coronary intervention within 2 months
  • Known aortic stenosis, hypertrophic cardiomyopathy.
  • Inability to give informed consent

Sites / Locations

  • Emory University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Nebivolol followed by Metoprolol XL

Metoprolol XL followed by Nebivolol

Arm Description

Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.

Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.

Outcomes

Primary Outcome Measures

Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks
Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.
Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks
Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.

Secondary Outcome Measures

Full Information

First Posted
January 12, 2010
Last Updated
March 13, 2017
Sponsor
Emory University
Collaborators
Forest Laboratories
search

1. Study Identification

Unique Protocol Identification Number
NCT01049009
Brief Title
The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension
Official Title
The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
December 2009 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
June 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Emory University
Collaborators
Forest Laboratories

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
High blood pressure (hypertension) is called the "silent killer" because many people do not know they have it, and do not know when it is well controlled. Unfortunately, over time uncontrolled hypertension can cause irreversible organ damage that can lead to heart attack, stroke, heart failure, and kidney failure. If a person cannot control their blood pressure with diet and exercise, doctors often prescribe medications to help control the blood pressure. Nebivolol is a medication that has been recently approved by the FDA for the treatment of hypertension. Our study will investigate whether treatment with nebivolol, as compared to another medication called metoprolol, in African Americans with hypertension will be more effective in protecting blood vessels against the harmful effects of high blood pressure. Over time high blood pressure causes hardening of the arteries (atherosclerosis) which leads to narrowing of the blood vessels and reduces blood flow to our organs. Arteries also relax and contract naturally, which further changes the blood supply. When arteries are narrowed, exercise can bring on a condition in which the blood supply is inadequate, and this might result in the sensation of pain. Cells lining our blood vessels produce a variety of substances that normally cause arteries to relax. Two of these substances are called nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF). We are trying to determine the nature of these substances in African Americans with high blood pressure and how it is affected by nebivolol and metoprolol. One way to determine this is to inject drugs such as L-NMMA (N(G)-monomethyl-L-arginine) or TEA (tetraethylammonium chloride), which block the production of NO and EDHF respectively, and then study what happens to the blood flow at rest and during exercise. It is our thought that nebivolol, in comparison to metoprolol, will increase the substances that naturally cause arteries to relax and improve blood supply.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
High Blood Pressure
Keywords
Nitric Oxide, Adrenergic beta-Antagonists, Antihypertensive Agents, Vasodilator Agents, Anti-Arrhythmia Agents, Sympatholytics, Vascular Resistance, Neurotransmitter Agents, Cardiovascular Diseases, Metoprolol succinate, Therapeutic Uses, Metoprolol, Vascular Diseases, Nebivolol, Cardiovascular Agents, Endothelium-Dependent Relaxing Factors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
91 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Nebivolol followed by Metoprolol XL
Arm Type
Active Comparator
Arm Description
Subjects are randomized to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after cross over.
Arm Title
Metoprolol XL followed by Nebivolol
Arm Type
Active Comparator
Arm Description
Subjects are randomized to Metoprolol XL 50mg and titrate to Metoprolol XL 100mg two weeks after drug initiation. Ten weeks after titration subjects will cross over to Nebivolol 5mg and titrate to Nebivolol 10mg two weeks after cross over.
Intervention Type
Drug
Intervention Name(s)
Nebivolol
Intervention Description
Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then "cross over" to take 10 weeks of the comparator drug.
Intervention Type
Drug
Intervention Name(s)
Metoprolol XL
Intervention Description
Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then "cross over" to take 10 weeks of the comparator drug.
Primary Outcome Measure Information:
Title
Endothelial Function Measured by Forearm Blood Flow (FBF) at 12 Weeks
Description
Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.
Time Frame
12 weeks
Title
Endothelial Function Measured by Forearm Blood Flow (FBF) at 24 Weeks
Description
Forearm blood flow measured by venous occlusion plethysmography at rest, after administration of N(G)-monomethyl-L-arginine (L-NMMA) and tetraethylammonium chloride (TEA), after administration of L-NMMA, TEA, and acetylcholine, and after administration of L-NMMA, TEA, and exercise. Unit of Measure refers to volume of blood (mL) per 100 mL of forearm tissue per minute.
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or post-menopausal females aged 18-80 years. Subjects self-identified as black or African-American. Diagnosis of hypertension. Patients on current anti-hypertensive therapy that does not include beta blockade should have BP >135/85. Patients on anti-hypertensive therapy including beta blockers will have their beta blockers discontinued gradually over 2 weeks before enrolment. Concomitant therapy: Patients will be allowed to be on concomitant therapy with aspirin, statins, thiazide diuretics, calcium antagonists (for treatment of hypertension), clonidine, or vasodilators. Patients will be on stable medical therapy for at least 2 months before recruitment. Patients with previous treatment with beta adrenergic blockers (metoprolol, propranolol, atenolol, and labetalol) will also be eligible to participate, but will be randomized to the study beta blocker. Exclusion Criteria: Initiation or change in dose of statin or other anti-hypertensive therapy within 2 months before the study Inability to return to Emory for follow-up testing Age < 21 or >80 years Premenopausal females with potential for pregnancy Acute infection in previous 2 weeks On angiotensin antagonists (ACE inhibitors or ARBs) History of substance abuse Current neoplasm Chronic renal failure [creatinine > 2.5 mg/dL] or liver failure (liver enzymes >2X normal) Acute coronary syndrome, Class IV heart failure, CVA, coronary intervention within 2 months Known aortic stenosis, hypertrophic cardiomyopathy. Inability to give informed consent
Facility Information:
Facility Name
Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
26285691
Citation
Neuman RB, Hayek SS, Poole JC, Rahman A, Menon V, Kavtaradze N, Polhemus D, Veledar E, Lefer DJ, Quyyumi AA. Nitric Oxide Contributes to Vasomotor Tone in Hypertensive African Americans Treated With Nebivolol and Metoprolol. J Clin Hypertens (Greenwich). 2016 Mar;18(3):223-31. doi: 10.1111/jch.12649. Epub 2015 Aug 19.
Results Reference
result
Available IPD and Supporting Information:
Available IPD/Information Type
Publication
Available IPD/Information URL
https://www.ncbi.nlm.nih.gov/pubmed/26285691
Available IPD/Information Identifier
26285691

Learn more about this trial

The Effect of Nebivolol on Endothelial Dysfunction in African Americans With Hypertension

We'll reach out to this number within 24 hrs